The Journal of Immunology · 2001 · 154 citations · 53 references
Life SciencesImmunologyInfectious DiseasesAdaptive ImmunityCancer ImmunologyVaccinologyCancer VaccinesCell-mediated ImmunityDendritic Cell BiologyVaccinationViral VaccinesVirus-like Particle VaccinesAntigen-specific T Cell ResponsesCellular Immune Response To VirusesDendritic Cell Antigen PresentationHpv Vaccine EfficacyImmune Response To HpvImmunogenicity EffectsViral Immune ResponsesVirus-like Particles
Human papillomavirus (HPV)-derived chimeric virus-like particles (VLPs) are the leading candidate vaccine for the treatment or prevention of cervical cancer in humans. Dendritic cells (DCs) are the most potent inducers of immune responses and here we show for the first time evidence for binding of chimeric HPV-16 VLPs to human peripheral blood-derived DCS: Incubation of immature human DCs with VLPs for 48 h induced a significant up-regulation of the CD80 and CD83 molecules as well as secretion of IL-12. Confocal microscopy analysis revealed that cell surface-bound chimeric VLPs were taken up by DCS: Moreover, DCs loaded with chimeric HPV-16 L1L2-E7 VLPs induced an HLA-*0201-restricted human T cell response in vitro specific for E7-derived peptides. These results clearly demonstrate that immature human DCs are fully activated by chimeric HPV-16 VLPs and subsequently are capable of inducing endogenously processed epitope-specific human T cell responses in vitro. Overall, these findings could explain the high immunogenicity and efficiency of VLPs as vaccines.
53
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Frank O. Nestlé, Selma Alijagic, Michel Gilliet et al. · Nature Medicine · 1998 · 2.9K citations
Medicine, Immunology, Oncology +14
Birthe Sauter, Matthew L. Albert, Loise M. Francisco et al. · The Journal of Experimental Medicine · 2000 · 1.4K citations · Full text
Beatrice Thurner, Ina Haendle, Claudia Röder et al. · The Journal of Experimental Medicine · 1999 · 1.2K citations · Full text
Medicine, Immunology, Oncology +17